Dr. Kaufman on Avelumab in Merkel Cell Carcinoma
2 Views
administrator
07/17/23
Howard L. Kaufman, MD, chief surgical officer, associate director for clinical science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses the phase II JAVELIN Merkel 200 study examining avelumab as a treatment for patients with Merkel cell carcinoma.
-
Category
Show more
Facebook Comments
No comments found